Effectiveness of valsartan for treatment of hypertension: Patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study)

Patricia Van Der Niepen, Annemie Woestenburg, Heidi Brié, Stefaan Vancayzeele, Karen MacDonald, Kris Denhaerynck, Christopher Lee, Christine Hermans, Ivo L Abraham

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

BACKGROUND: Patient- and clinician-related factors may explain variability in blood pressure (BP) outcomes and the differences between real-world effectiveness and efficacy seen in randomized trials of antihypertensive agents. OBJECTIVE: To examine the effectiveness of 90 days of second-line valsartan treatment and identify patient- and physician-level determinants that impact BP outcomes. METHODS: A prospective, multicenter, multilevel pharmacoepidemiologic study was conducted in 3194 hypertensive patients (systolic BP [SBP] ≥140 mm Hg, diastolic BP [DBP] ≥90 mm Hg; for diabetic patients, ≥130 and ≥80 mm Hg, respectively) treated by 504 general practitioners (GPs). Statistical analysis included heuristic data mining, and hierarchical linear and logistic modeling. RESULTS: With valsartan treatment, mean ± SD SBP decreased from 154.4 ± 15.5 mmHg to 139.0 ± 12.0 mmHg and mean DBP decreased from 91.3 ± 9.2 mmHg to 82.6 ± 7.4 mmHg. SBP control rates increased from 9.0% to 38.6%, DBP from 25.5% to 65.5%, and combined SBP/DBP from 7.3% to 34.4%. A highly vulnerable cohort (n = 1063; 35.4%) of patients was identified. Twenty-four percent of variability in SBP and 25% of variability in DBP at 90 days were attributable to physician-related variables: guideline-compliant BP management, hypertension, practice patterns, hypertensive patient volume, and years in practice. The remaining 76% and 75% of variability in SBP and DBP, respectively, were due to patient factors, notably diabetes and related complications, vulnerability to uncontrolled BP, nonadherence, cardiovascular risk, and age. Similar factors increased the odds of treatment nonresponse, with diabetes being the single largest determinant of uncontrolled SBP (OR 8.99), DBP (OR 20.35), and combined SBP/DBP (OR = 18.64). CONCLUSIONS: Valsartan is effective and well tolerated in a broad range of patients in whom first-line antihypertensive treatment failed or was not tolerated. Mitigating the impact of BP-elevating variables and optimizing the effect of BP-lowering factors provides therapeutic benefits incremental to valsartan's pharmacologic effect. Improving outcomes in hypertensive patients involves 3 steps: (1) identifying, intuitively rather than formally, patients less likely to achieve BP control; (2) targeting modifiable or manageable patient- and physician-level determinants with BP-elevating or BP-lowering effects; and (3) managing variables that increase the odds and optimizing those that lower the odds of uncontrolled BP.

Original languageEnglish (US)
Pages (from-to)849-861
Number of pages13
JournalAnnals of Pharmacotherapy
Volume43
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Valsartan
Outcome Assessment (Health Care)
Blood Pressure
Hypertension
Physicians
Antihypertensive Agents

Keywords

  • Angiotensin II receptor blockers
  • Effectiveness
  • Hypertension
  • Outcomes
  • Pharmacoepidemiology
  • Valsartan

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effectiveness of valsartan for treatment of hypertension : Patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study). / Van Der Niepen, Patricia; Woestenburg, Annemie; Brié, Heidi; Vancayzeele, Stefaan; MacDonald, Karen; Denhaerynck, Kris; Lee, Christopher; Hermans, Christine; Abraham, Ivo L.

In: Annals of Pharmacotherapy, Vol. 43, No. 5, 05.2009, p. 849-861.

Research output: Contribution to journalArticle

Van Der Niepen, P, Woestenburg, A, Brié, H, Vancayzeele, S, MacDonald, K, Denhaerynck, K, Lee, C, Hermans, C & Abraham, IL 2009, 'Effectiveness of valsartan for treatment of hypertension: Patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study)', Annals of Pharmacotherapy, vol. 43, no. 5, pp. 849-861. https://doi.org/10.1345/aph.1L576
Van Der Niepen, Patricia ; Woestenburg, Annemie ; Brié, Heidi ; Vancayzeele, Stefaan ; MacDonald, Karen ; Denhaerynck, Kris ; Lee, Christopher ; Hermans, Christine ; Abraham, Ivo L. / Effectiveness of valsartan for treatment of hypertension : Patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study). In: Annals of Pharmacotherapy. 2009 ; Vol. 43, No. 5. pp. 849-861.
@article{7b6866ed2af44ba5aefda11d167b098a,
title = "Effectiveness of valsartan for treatment of hypertension: Patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study)",
abstract = "BACKGROUND: Patient- and clinician-related factors may explain variability in blood pressure (BP) outcomes and the differences between real-world effectiveness and efficacy seen in randomized trials of antihypertensive agents. OBJECTIVE: To examine the effectiveness of 90 days of second-line valsartan treatment and identify patient- and physician-level determinants that impact BP outcomes. METHODS: A prospective, multicenter, multilevel pharmacoepidemiologic study was conducted in 3194 hypertensive patients (systolic BP [SBP] ≥140 mm Hg, diastolic BP [DBP] ≥90 mm Hg; for diabetic patients, ≥130 and ≥80 mm Hg, respectively) treated by 504 general practitioners (GPs). Statistical analysis included heuristic data mining, and hierarchical linear and logistic modeling. RESULTS: With valsartan treatment, mean ± SD SBP decreased from 154.4 ± 15.5 mmHg to 139.0 ± 12.0 mmHg and mean DBP decreased from 91.3 ± 9.2 mmHg to 82.6 ± 7.4 mmHg. SBP control rates increased from 9.0{\%} to 38.6{\%}, DBP from 25.5{\%} to 65.5{\%}, and combined SBP/DBP from 7.3{\%} to 34.4{\%}. A highly vulnerable cohort (n = 1063; 35.4{\%}) of patients was identified. Twenty-four percent of variability in SBP and 25{\%} of variability in DBP at 90 days were attributable to physician-related variables: guideline-compliant BP management, hypertension, practice patterns, hypertensive patient volume, and years in practice. The remaining 76{\%} and 75{\%} of variability in SBP and DBP, respectively, were due to patient factors, notably diabetes and related complications, vulnerability to uncontrolled BP, nonadherence, cardiovascular risk, and age. Similar factors increased the odds of treatment nonresponse, with diabetes being the single largest determinant of uncontrolled SBP (OR 8.99), DBP (OR 20.35), and combined SBP/DBP (OR = 18.64). CONCLUSIONS: Valsartan is effective and well tolerated in a broad range of patients in whom first-line antihypertensive treatment failed or was not tolerated. Mitigating the impact of BP-elevating variables and optimizing the effect of BP-lowering factors provides therapeutic benefits incremental to valsartan's pharmacologic effect. Improving outcomes in hypertensive patients involves 3 steps: (1) identifying, intuitively rather than formally, patients less likely to achieve BP control; (2) targeting modifiable or manageable patient- and physician-level determinants with BP-elevating or BP-lowering effects; and (3) managing variables that increase the odds and optimizing those that lower the odds of uncontrolled BP.",
keywords = "Angiotensin II receptor blockers, Effectiveness, Hypertension, Outcomes, Pharmacoepidemiology, Valsartan",
author = "{Van Der Niepen}, Patricia and Annemie Woestenburg and Heidi Bri{\'e} and Stefaan Vancayzeele and Karen MacDonald and Kris Denhaerynck and Christopher Lee and Christine Hermans and Abraham, {Ivo L}",
year = "2009",
month = "5",
doi = "10.1345/aph.1L576",
language = "English (US)",
volume = "43",
pages = "849--861",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "5",

}

TY - JOUR

T1 - Effectiveness of valsartan for treatment of hypertension

T2 - Patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study)

AU - Van Der Niepen, Patricia

AU - Woestenburg, Annemie

AU - Brié, Heidi

AU - Vancayzeele, Stefaan

AU - MacDonald, Karen

AU - Denhaerynck, Kris

AU - Lee, Christopher

AU - Hermans, Christine

AU - Abraham, Ivo L

PY - 2009/5

Y1 - 2009/5

N2 - BACKGROUND: Patient- and clinician-related factors may explain variability in blood pressure (BP) outcomes and the differences between real-world effectiveness and efficacy seen in randomized trials of antihypertensive agents. OBJECTIVE: To examine the effectiveness of 90 days of second-line valsartan treatment and identify patient- and physician-level determinants that impact BP outcomes. METHODS: A prospective, multicenter, multilevel pharmacoepidemiologic study was conducted in 3194 hypertensive patients (systolic BP [SBP] ≥140 mm Hg, diastolic BP [DBP] ≥90 mm Hg; for diabetic patients, ≥130 and ≥80 mm Hg, respectively) treated by 504 general practitioners (GPs). Statistical analysis included heuristic data mining, and hierarchical linear and logistic modeling. RESULTS: With valsartan treatment, mean ± SD SBP decreased from 154.4 ± 15.5 mmHg to 139.0 ± 12.0 mmHg and mean DBP decreased from 91.3 ± 9.2 mmHg to 82.6 ± 7.4 mmHg. SBP control rates increased from 9.0% to 38.6%, DBP from 25.5% to 65.5%, and combined SBP/DBP from 7.3% to 34.4%. A highly vulnerable cohort (n = 1063; 35.4%) of patients was identified. Twenty-four percent of variability in SBP and 25% of variability in DBP at 90 days were attributable to physician-related variables: guideline-compliant BP management, hypertension, practice patterns, hypertensive patient volume, and years in practice. The remaining 76% and 75% of variability in SBP and DBP, respectively, were due to patient factors, notably diabetes and related complications, vulnerability to uncontrolled BP, nonadherence, cardiovascular risk, and age. Similar factors increased the odds of treatment nonresponse, with diabetes being the single largest determinant of uncontrolled SBP (OR 8.99), DBP (OR 20.35), and combined SBP/DBP (OR = 18.64). CONCLUSIONS: Valsartan is effective and well tolerated in a broad range of patients in whom first-line antihypertensive treatment failed or was not tolerated. Mitigating the impact of BP-elevating variables and optimizing the effect of BP-lowering factors provides therapeutic benefits incremental to valsartan's pharmacologic effect. Improving outcomes in hypertensive patients involves 3 steps: (1) identifying, intuitively rather than formally, patients less likely to achieve BP control; (2) targeting modifiable or manageable patient- and physician-level determinants with BP-elevating or BP-lowering effects; and (3) managing variables that increase the odds and optimizing those that lower the odds of uncontrolled BP.

AB - BACKGROUND: Patient- and clinician-related factors may explain variability in blood pressure (BP) outcomes and the differences between real-world effectiveness and efficacy seen in randomized trials of antihypertensive agents. OBJECTIVE: To examine the effectiveness of 90 days of second-line valsartan treatment and identify patient- and physician-level determinants that impact BP outcomes. METHODS: A prospective, multicenter, multilevel pharmacoepidemiologic study was conducted in 3194 hypertensive patients (systolic BP [SBP] ≥140 mm Hg, diastolic BP [DBP] ≥90 mm Hg; for diabetic patients, ≥130 and ≥80 mm Hg, respectively) treated by 504 general practitioners (GPs). Statistical analysis included heuristic data mining, and hierarchical linear and logistic modeling. RESULTS: With valsartan treatment, mean ± SD SBP decreased from 154.4 ± 15.5 mmHg to 139.0 ± 12.0 mmHg and mean DBP decreased from 91.3 ± 9.2 mmHg to 82.6 ± 7.4 mmHg. SBP control rates increased from 9.0% to 38.6%, DBP from 25.5% to 65.5%, and combined SBP/DBP from 7.3% to 34.4%. A highly vulnerable cohort (n = 1063; 35.4%) of patients was identified. Twenty-four percent of variability in SBP and 25% of variability in DBP at 90 days were attributable to physician-related variables: guideline-compliant BP management, hypertension, practice patterns, hypertensive patient volume, and years in practice. The remaining 76% and 75% of variability in SBP and DBP, respectively, were due to patient factors, notably diabetes and related complications, vulnerability to uncontrolled BP, nonadherence, cardiovascular risk, and age. Similar factors increased the odds of treatment nonresponse, with diabetes being the single largest determinant of uncontrolled SBP (OR 8.99), DBP (OR 20.35), and combined SBP/DBP (OR = 18.64). CONCLUSIONS: Valsartan is effective and well tolerated in a broad range of patients in whom first-line antihypertensive treatment failed or was not tolerated. Mitigating the impact of BP-elevating variables and optimizing the effect of BP-lowering factors provides therapeutic benefits incremental to valsartan's pharmacologic effect. Improving outcomes in hypertensive patients involves 3 steps: (1) identifying, intuitively rather than formally, patients less likely to achieve BP control; (2) targeting modifiable or manageable patient- and physician-level determinants with BP-elevating or BP-lowering effects; and (3) managing variables that increase the odds and optimizing those that lower the odds of uncontrolled BP.

KW - Angiotensin II receptor blockers

KW - Effectiveness

KW - Hypertension

KW - Outcomes

KW - Pharmacoepidemiology

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=65749089065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749089065&partnerID=8YFLogxK

U2 - 10.1345/aph.1L576

DO - 10.1345/aph.1L576

M3 - Article

C2 - 19351876

AN - SCOPUS:65749089065

VL - 43

SP - 849

EP - 861

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 5

ER -